Explore the latest in diabetic retinopathy, including updates in epidemiology and advances in diagnosis and treatment of the disorder.
This Viewpoint posits that the correlation between central subfield thickness and visual acuity is low and suggests that anatomical and physiologic measurements should be used to assess visual acuity as well.
This cross-sectional study analyzes severity of diabetic retinopathy in patients whose eyes were examined via the Early Treatment Diabetic Retinopathy Study (ETDRS) 7-field imaging and ultrawide-field (UWF) imaging techniques.
This case report describes a patient with a 20-year history of type 2 diabetes with gradual painless unilateral vision loss associated with this condition.
This randomized clinical trial reports that 5-year visual acuity results were similar in patients treated with panretinal photocoagulation and ranibizumab for proliferative diabetic retinopathy.
This diagnostic study evaluates an artificial intelligence (AI)–based system for diagnosing diabetic retinopathy using retinal images in a primary care setting vs the gold standard of diagnosis by an ophthalmologist.
This case report describes panretinal photocoagulation and intravitreal bevacizumab treatment in a patient with foveal retinal neovascularization.
This cross-sectional study quantifies capillary nonperfusion in 3 vascular plexuses in the macula of eyes of patients with diabetes and various retinopathy severity using projection-resolved optical coherence tomography angiography (OCTA).
A young pregnant woman with proliferative diabetic retinopathy presents with subacute bilateral vision loss. Examination reveals mild optic nerve head edema and macular edema. What would you do next?
A 63-year-old man with type 2 diabetes for 10 years was seen with decreased vision in both eyes. He was diagnosed as having nonproliferative diabetic retinopathy with macular edema in both eyes and received 3 intravitreal bevacizumab injections at 4 weekly intervals and 2 intravitreal triamcinalone acetonide injections in both eyes, with minimal resolution of edema. What would you do next?
This overview of systematic reviews and meta-analyses evaluates systemic adverse events associated with intravitreal anti-vascular endothelial growth factor medications used to treat neovascular age-related macular degeneration, diabetic macular edema, and retinal vein occlusion.
A 67-year-old African American man with a history of hypertension and type 2 diabetes after kidney transplant presented with sudden-onset, painless vision loss in the right eye and several large pigment epithelial detachments with associated tears and scrolling of the retinal pigment epithelium on optical coherence tomography. What would you do next?
This cohort study investigates aqueous humor cytokine level changes in response to intravitreal ranibizumab therapy for the management of diabetic macular edema.
This multisite cross-sectional study compares subjective and precise quantitative classification of diabetic retinopathy lesion distribution from nonmydriadic ultrawidefield pseudocolor images.
This post hoc analysis of data from a randomized clinical trial evaluates the association of repeated ranibizumab injections on macular perfusion in patients with diabetic macular edema as compared with laser monotherapy or ranibizumab and laser combination therapy.
This cross-sectional study evaluates the repeatability and agreement of best-corrected visual acuity using the Early Treatment Diabetic Retinopathy Study number chart or Landolt C chart compared with the Early Treatment Diabetic Retinopathy Study alphabet chart in healthy and diseased eyes.
This secondary analysis of a randomized clinical trial assesses outcomes of diabetic macular edema persisting at least 24 weeks after randomization to treatment with 2.0-mg aflibercept, 1.25-mg bevacizumab, or 0.3-mg ranibizumab.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: